NanoViricides, Inc. (NNVC.PK) Reports That It Is Evaluating Purchase Of The New Facility And cGMP Pilot Production Plant Instead Of A Lease
2/20/2014 9:07:26 AM
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company") reported today that construction of the modern R&D Lab and cGMP Clinical Production facility in Shelton, CT, is nearing completion with some weather-related delays. The Company reports that the R&D lab section of the facility is ahead of schedule. Once construction of the cGMP Clean Room Production Suite is completed, the project will enter the facility testing and validation phase. The Company is performing certain scale-up studies and production of the quantities of FluCide™ needed for the “Tox Package” study at its current facility, as previously reported. The Company anticipates transitioning staff to the new facility upon obtaining a Certificate of Occupancy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by